Patents Assigned to TenGen Biomedical Company
  • Mammal-specific growth-defective arbovirus
    Patent number: 12098393
    Abstract: Arbovirus carries an altered furin cleavage site that results in enhanced cleavage of a precursor polyprotein, such as, prE2 or prM. Dengue virus particles can have an amino acid alteration within amino acids 80-130 of prM. Zika virus particles can have alterations at amino residues at and/or about the furin cleavage site. The virus can be produced in insect cells. The virus does not form progeny virus in mammal cells.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: September 24, 2024
    Assignee: Tengen Biomedical Company
    Inventors: Xiaowu Pang, Xinbin Gu
  • Flavivirus vaccine
    Patent number: 10040824
    Abstract: Replicon virus-like particles can be used as flavivirus vaccines.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: August 7, 2018
    Assignee: Tengen Biomedical Company
    Inventors: Xiaowu Pang, Xinbin Gu
  • Virus-Like Particle Containing A Dengue Recombinant Replicon
    Publication number: 20090197319
    Abstract: A diagnostic assay for detecting antibody, in part, to human papilloma virus includes a virus-like particle that expresses human papilloma virus antigen.
    Type: Application
    Filed: January 9, 2008
    Publication date: August 6, 2009
    Applicant: TenGen Biomedical Company
    Inventor: Xiaowu Pang
  • FLAVIVIRUS VACCINE
    Publication number: 20070249032
    Abstract: Replicon virus-like particles can be used as flavivirus vaccines.
    Type: Application
    Filed: January 11, 2007
    Publication date: October 25, 2007
    Applicant: TenGen Biomedical Company
    Inventors: Xiaowu Pang, Xinbin Gu